Potocki–Lupski syndrome

Potocki–Lupski syndrome, abbreviated PTLS, is a rare contiguous gene duplication syndrome caused by an extra copy of the proximal short arm of chromosome 17 at band 17p11.2, and it combines infantile hypotonia, global developmental delay, moderate intellectual disability, autism spectrum disorder and congenital cardiovascular anomalies.

It is the reciprocal duplication of the 17p11.2 deletion that causes Smith–Magenis syndrome, occurs in about 1 in 25,000 births according to GeneReviews, and is usually caused by a recurrent 3.7 megabase duplication mediated by low-copy repeats.

Terminology and classification

• The eponym Potocki–Lupski syndrome honours Lorraine Potocki and James Lupski, who described the duplication phenotype in 2000, and the abbreviation PTLS is used throughout the clinical literature.
• Synonymous labels are 17p11.2 microduplication syndrome, 17p11.2 duplication syndrome and trisomy 17p11.2, all of which describe the same copy-number gain rather than a distinct entity.
• ICD-10 places chromosomal duplications of this region in Q92.3, duplication of other parts of chromosome 17, a category that also contains duplications with different breakpoints and different phenotypes.
• ICD-11 release 2025-01 assigns the specific code LD41.G1, which is more granular than ICD-10 and should always be quoted with the release because WHO revises the linearisation on a rolling cycle.
• Cross-references are unusually complete for a duplication syndrome: MONDO:0012574, Orphanet ORPHA:1713, OMIM 610883, MedGen 444010 and UMLS C2931246, MeSH C538355, GARD 10145, SNOMED CT 734016004 and GeneReviews NBK447920.
• Orphanet classifies it as a rare developmental defect during embryogenesis with a prevalence class of 1 to 5 per 100,000, and the entity is the exact reciprocal of Smith–Magenis syndrome, in which the same interval is deleted.

History

• Smith–Magenis syndrome, the deletion counterpart, was described in 1986 by Smith, Magenis and colleagues, and the recognition of its 17p11.2 deletion created the expectation that a reciprocal duplication must exist.
• In 1991 Lupski and colleagues showed that a 17p11.2 duplication causes Charcot–Marie–Tooth disease type 1A through a third copy of PMP22, establishing that dosage gain in this region is pathogenic.
• Potocki, Lupski and colleagues described the developmental duplication syndrome in 2000 in Nature Genetics and identified it as the homologous recombination reciprocal of the Smith–Magenis deletion.
• Early reports assumed that PMP22 dosage explained the whole phenotype, but work in the early 2000s identified RAI1 as the dosage-sensitive gene responsible for the cognitive and behavioural features, correcting that assumption.
• Chromosomal microarray replaced G-banded karyotyping after the 2010 ACMG consensus endorsed it as a first-tier test for developmental delay, which sharply increased ascertainment of submicroscopic duplications.
• Later milestones were the 2018 ACC and AHA guideline for adults with congenital heart disease, which set surveillance rules for the aortic and left ventricular outflow lesions seen in PTLS, and the 2021 ACMG technical standards for constitutional microarray analysis.

Epidemiology

• GeneReviews gives a prevalence of approximately 1 in 25,000 births, a figure derived from ascertainment of patients with developmental delay rather than from population newborn screening.
• Orphanet records the same entity with a prevalence class of 1 to 5 per 100,000, which corresponds to between 1 in 20,000 and 1 in 100,000 and is consistent with the GeneReviews estimate.
• The sex distribution is approximately equal, and no ethnic or geographic cluster has been reported, which is typical of a rearrangement generated de novo by unequal crossing over.
• Most propositi carry a de novo duplication, but transmission from an affected or mildly affected parent is documented, so parental testing and genetic counselling are mandatory after a positive result.
• About two thirds of patients carry the recurrent 3.7 megabase duplication, and the remaining third carry non-recurrent duplications ranging from 0.41 to 19.7 megabases with different breakpoints.
• Congenital heart disease is present in about 40 per cent of patients, with atrial and ventricular septal defects, bicuspid aortic valve, aortic root dilation and left ventricular outflow tract obstruction accounting for most of the burden.
• Autism spectrum disorder is diagnosed in about 60 per cent of patients in the cohorts reported to date, and attention deficit hyperactivity disorder and anxiety disorders are also common.
• Named surveillance sources are the GeneReviews chapter NBK447920, which publishes updated prevalence and management recommendations, and Orphanet ORPHA:1713, which supplies the European prevalence class.

Pathophysiology

• The duplication arises by non-allelic homologous recombination between low-copy repeat gene clusters that flank the 17p11.2 interval, which is the same mechanism that produces the reciprocal Smith–Magenis deletion.
• Recurrent 3.7 megabase duplications are mediated by the REP A to REP D repeat clusters, whereas non-recurrent duplications with unusual breakpoints arise through replication-based mechanisms such as fork stalling and template switching.
• RAI1 at 17p11.2 is the principal dosage-sensitive gene: a third copy raises RAI1 transcript and protein levels, and loss of one copy in Smith–Magenis syndrome produces the opposite phenotype.
• RAI1 encodes a transcriptional regulator that modulates genes involved in neuronal differentiation and synaptic function, and its overexpression is thought to perturb the same developmental programmes that its loss disrupts.
• Transgenic mice carrying extra copies of Rai1 reproduce growth retardation, increased anxiety-like behaviour, altered circadian activity and sleep fragmentation, which supports a direct dosage effect rather than a positional disruption of neighbouring genes.
• The duplication size correlates only loosely with severity, and patients with the recurrent 3.7 megabase duplication can be more severely affected than patients with smaller duplications, so modifying factors remain unexplained.

Clinical features

• Infants present with hypotonia, poor suck, swallowing difficulty and failure to thrive, and feeding problems are often the first reason for medical attention before developmental delay is appreciated.
• Global developmental delay affects essentially all patients, and expressive speech is the most severely delayed domain, with many children speaking few words until school age.
• Intellectual disability is usually mild to moderate, and the behavioural profile includes autism spectrum disorder, attention deficits, anxiety, shyness and sometimes sleep-seeking or repetitive behaviours.
• Cardiovascular findings include atrial and ventricular septal defects, bicuspid aortic valve, aortic root dilation, left ventricular outflow tract obstruction and, rarely, hypoplastic left heart syndrome.
• Sleep-disordered breathing is a recurring problem, with obstructive and central apnoeas, loud snoring and daytime somnolence, and polysomnography frequently reveals fragmentation of sleep architecture.
• Growth hormone deficiency with hypoglycaemia, dysphagia with aspiration risk, constipation, scoliosis and, in a minority, seizures complete the phenotype and are the named complications that drive morbidity.

Diagnosis

• Diagnosis requires detection of the 17p11.2 duplication, and chromosomal microarray is the first-tier test because G-banded karyotyping cannot resolve a 3.7 megabase gain reliably.
• Multiplex ligation-dependent probe amplification and fluorescence in situ hybridisation can confirm the duplication and are used when microarray is unavailable or when a rapid targeted answer is needed.
• Microarray also defines the size and breakpoints, which matters because non-recurrent duplications extending beyond 17p11.2 may include additional genes and produce a different phenotype.
• Parental microarray or fluorescence in situ hybridisation is performed after a positive result to distinguish de novo from inherited duplication, and this determines recurrence risk for the family.
• The differential diagnosis includes Smith–Magenis syndrome from deletion of the same band, 22q11.2 duplication syndrome, Down syndrome, Williams syndrome, Prader–Willi syndrome and MECP2 duplication syndrome.
• Baseline evaluation after diagnosis comprises echocardiography, polysomnography, growth and endocrine assessment with insulin-like growth factor 1, swallowing evaluation and developmental and behavioural testing.
• No clinical diagnostic criteria exist, so the diagnosis rests entirely on the copy-number result, and a normal karyotype never excludes the syndrome.

Management

• Management is multidisciplinary and symptom-directed, with no therapy that removes the duplicated segment or reverses the neurodevelopmental course.
• Speech and language therapy, occupational therapy and physiotherapy target expressive language, feeding skills and hypotonia, and early intervention should begin as soon as the diagnosis is made.
• Growth hormone replacement with somatropin is used when provocation testing confirms growth hormone deficiency, and hypoglycaemia in infancy requires glucose monitoring and feeding support.
• Obstructive sleep apnoea is managed with adenotonsillectomy, positive airway pressure or nocturnal oxygen according to polysomnography, and sleep studies should be repeated as the child grows.
• Attention deficit hyperactivity disorder may respond to methylphenidate, and melatonin is used for sleep-onset difficulties, while behavioural therapy and school support address autism-related needs.
• Cardiac surveillance follows the 2018 ACC and AHA adult congenital heart disease guideline, with serial echocardiography for aortic root dimensions and left ventricular outflow tract gradients.
• Antibiotic prophylaxis before dental procedures is reserved for patients with a prosthetic valve, previous endocarditis or specific unrepaired lesions rather than given to every patient with PTLS.
• Prognosis for survival is good in the absence of complex congenital heart disease, and most adults live independently or with supported employment, although speech and literacy deficits persist.
• Genetic counselling should explain the approximately 50 per cent recurrence risk when a parent carries the duplication and the low but non-zero gonadal mosaicism risk after a de novo result.

Research and controversies

• RAI1 transgenic and knockout mouse models are the main experimental platform, and they have linked RAI1 dosage to growth, anxiety, circadian rhythm and sleep, but no RAI1-targeted therapy has entered clinical trials.
• Whether the phenotype is driven by RAI1 alone or by the combined dosage of several genes in the interval is unresolved, and patients with atypical breakpoints are the natural experiment that may answer it.
• Duplication size explains little of the variability, and modifier genes, imprinting or environmental factors are proposed explanations without direct evidence in humans.
• Growth hormone deficiency is recognised but its prevalence, the optimal provocation protocol and the long-term effect of replacement on adult height have not been defined in prospective cohorts.
• Adult outcome data are scarce because most published cohorts are paediatric, and the frequency of psychiatric disorders, aortic dissection and late sleep apnoea in adults is unknown.
• Patient registries and natural history studies are the stated priority of the GeneReviews authors, and international collaboration is needed because individual centres follow only a handful of patients.